Embecta faces securities class action after 57.8% stock plunge on May 5

The lawsuit in New Jersey alleges the medical device company misled investors about the resilience of its insulin pen needle business before reporting weak Q2 2026 results and cutting its dividend.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.